PASG – passage bio, inc. (US:NASDAQ)
Passage Bio, Inc. (NASDAQ: PASG) had its price target lowered by analysts at Chardan Capital from $7.00 to $6.00. They now have a "buy" rating on the stock.
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com